Drug intelligence / Profile preview

DHP2306R2

Development stage: Unknown
Lead developer: Daehwa Pharmaceutical
Modality: Small Molecules

Overview

DHP2306R2 is a small molecule drug under development by DAE HWA PHARM for the treatment of musculoskeletal pain. It is being investigated in Phase 1 clinical trials, primarily to evaluate its safety and pharmacokinetic drug-drug interactions when administered alone or in combination with another investigational agent, DHP2306R1. The primary therapeutic area targeted by this compound includes nervous system diseases and skin and musculoskeletal diseases. As of now, detailed information about its mechanism of action or molecular target has not been disclosed[1][3][5].

Beyond the preview

Go deeper on DHP2306R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHP2306R2.

Explore the full profile